Dalbavancin for the treatment of acute bacterial skin and skin structure infections.

Related Articles

Dalbavancin for the treatment of acute bacterial skin and skin structure infections.

Infez Med. 2015 Dec 1;23(4):313-7

Authors: Esposito S, Noviello S, Leone S

Abstract
Dalbavancin is a novel parenteral lipoglycopeptide antibiotic approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in adults. Dalbavancin is highly active against common Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Dalbavancin has a prolonged half-life that allows for once weekly dosing. Phase III trials have demonstrated non-inferiority compared with vancomycin/linezolid in the treatment of ABSSSIs, including those sustained by MRSA.

PMID: 26700080 [PubMed - in process]